BioSpace News Archive

Can-Fite BioPharma Ltd. today announced that it discovered the mechanism of action (MOA) involved with the significant anti-cancer effect of Namodenoson in pancreatic carcinoma. Namodenoson de-regulates the Wnt signal transduction pathway, a key modulator of pancreatic carcinoma cell growth.

DexCom, Inc. (Nasdaq: DXCM) (“Dexcom”) announced today that it intends to offer, subject to market conditions and other factors, $1.0 billion aggregate principal amount of Convertible Senior Notes due 2028 (the “notes”) in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”).

Anavex Life Sciences Corp. today announced that it will issue financial results for its quarter ended March 31, 2023, on Tuesday, May 9, 2023.

LEXEO Therapeutics announced today that new data supporting its cardiac and neurological gene therapy programs will be presented at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) taking place May 16-20, 2023.

Harmony Biosciences Holdings, Inc. (“Harmony” or the “Company”) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today reported financial results and business updates for the quarter ended March 31, 2023.

AVRICORE HEALTH INC. (TSXV: AVCR) (the " Company " or “ AVCR ”) today is pleased to announce its audited final results for 2022.

Hygieia is extending its Series B funding round to $22 million with a lead investment from Firstime Ventures and additional investment from two strategic partners.

Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company, today announces its PICO Single Use Negative Pressure Wound Therapy Systems have received an Innovative Technology contract from Vizient, Inc. the nation’s largest member-driven health care performance improvement company.

Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for spesolimab as an investigational treatment for the prevention of flares in adults with generalized pustular psoriasis (GPP).

argenx announced that members of management will participate in a fireside chat at the BofA Securities 2023 Health Care Conference on Tuesday, May 9, 2023, at 8:00 a.m. P.T. in Las Vegas, NV.